Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA 2017 | Practical intricacies surrounding biosimilar adoption

Simon Cheesman • 6 Oct 2017
BOPA 2017
General Antibodies Rituximab

There are many intricacies surrounding the introduction of biosimilars. Here, Simon Cheesman, BPharm, MRPharmS from University College London Hospital (UCLH), London, UK discusses some of these issues, including whether patients need to be re-consented for treatment, the attitudes of health care professionals towards the adoption of biosimilars and the essential role pharmacists will serve. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.

More from Simon Cheesman

CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
2:14
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Simon Cheesman • 12 Oct 2018
The switch to biosimilar rituximab at UCH: 12 months on
0:54
The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman • 12 Oct 2018
An audit of infusion-related reactions with biosimilar rituximab in London
1:12
An audit of infusion-related reactions with biosimilar rituximab in London
Simon Cheesman • 6 Oct 2017
The introduction of biosimilar rituximab: a case study from the pharmacist's perspective
1:29
The introduction of biosimilar rituximab: a case study from the pharmacist's perspective
Simon Cheesman • 7 Oct 2017

Related Videos

Combining isatuximab, lenalidomide, oral cyclophosphamide, & dexamethasone for HR smoldering myeloma
4:53
Combining isatuximab, lenalidomide, oral cyclophosphamide, & dexamethasone for HR smoldering myeloma
Maher Salamoon • 9 Sep 2026
Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin
4:17
Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin
Maher Salamoon • 9 Sep 2026
Insights into the risk of pulmonary infections in patients with CLL treated with targeted agents
5:31
Insights into the risk of pulmonary infections in patients with CLL treated with targeted agents
Maher Salamoon • 8 Sep 2026
Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals